Evotec SE - ADR opened lower at $1.66, compared with its previous close of $1.69. In the last trading session, the stock traded between $1.64 and $1.69. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Evotec SE - ADR is now worth
$ 7.08
Resulting in a loss of
$ 92.92 (92.92%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.03 (-1.48%)
Day High
$1.69
Day Low
$1.64
Day Open
$1.66
Prev Close
$1.69
Volume
45,845
1W Return
6.05%
1M Return
21.98%
3M Return
-21.28%
6M Return
-45.59%
1Y Return
-43.94%
Fundamentals
Market Cap ($ Mn)
592
PE Ratio
-
PB Ratio
0.89
PEG Ratio
-
ROE
-11.97%
ROCE
-5.24%
EPS (TTM)
$-0.15
Investment Returns
1 Week
6.05%
1 Month
21.98%
3 Months
-21.28%
6 Months
-45.59%
9 Months
-52.16%
Financials
Quarterly
All values in $ Mn
171.2
Jun 25
163.9
Sep 25
253.3
Dec 25
156.6
Mar 26
143.5
Jun 26
164.9
Sep 26
Updates
6Nov
HC Wainwright raises Evotec price target to $5, maintains Buy rating
HC Wainwright & Co. raised the price target for Evotec from $4 to $5. The firm maintained its Buy rating on the stock. Analyst Swayampakula Ramakanth issued the revised recommendation.
6 days ago
5Nov
Evotec Q3FY26 Results: EPS misses estimate, EBITDA loss narrows
Q3FY26 Group revenue of €164.9 million missed consensus by 1.29%. Adjusted Group EBITDA loss narrowed to €1.6 million from €15.0 million YoY. FY2026 sales guidance affirmed at $656.004 million to $702.039 million. Horizon transformation delivered over 20% of annual run-rate savings target.
7 days ago
15Oct
Evotec SE appoints Joanna Holbrook as chief scientific officer
Dr. Joanna Holbrook appointed as Chief Scientific Officer and Management Board member effective November 1, 2026. Brings over 25 years of experience from Novo Nordisk, Biomodal, BenevolentAI, and academia. Will lead global scientific strategy focusing on AI, data science, and novel therapeutic modalities. Evotec operates with around 4,500 experts and partners with all Top 20 Pharma companies.
28 days ago
29Sep
Evotec CSO Cord Dohrmann to step down effective Sept 30, 2026
Dr. Cord Dohrmann steps down as CSO effective September 30, 2026. Departure is by mutual consent after 16 years of service. Search for successor is currently ongoing. Dohrmann served on Management Board since 2010.
1mo ago
13Aug
Evotec Q2 Results: EPS Misses Estimate, Sales Fall 14% YoY
Evotec's Q2 results showed a loss of $(0.15) per share, missing estimates by 150%, while sales dropped 14.08% YoY to $166.802 million, missing revenue forecasts by 21.46%. The widening loss and significant revenue shortfall indicate continued operational challenges.
3mo ago
13Aug
Evotec affirms FY26 sales guidance of $667M-$714M vs estimate
Evotec reaffirms its FY26 sales guidance of $667.470 million to $714.310 million, unchanged from prior statements. The outlook exceeds the consensus estimate of $673.750 million at the lower bound, reflecting stable operational expectations.
